- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05117567
Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia
A Personal Protection Package for Reducing Malaria Transmission in Forest-going Mobile and Migrant Populations in Lao PDR and Cambodia: A Stepped-wedge Trial With Nested Mixed-methods Study
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Over the last decade, the burden of malaria has fallen dramatically in the Greater Mekong Subregion, with deaths falling by 95% and cases by 76% between 2012 and 2019.The declining malaria burden in GMS has largely attributed by the deployment of interventions of malaria prevention tools such as long-lasting Insecticidal Nets (LLIN), and widespread availability of rapid diagnostic tests and artemisinin combination therapies. However, residual transmission still exists among high risk populations, particularly mobile and migrant populations who enter forests for work. New interventions targetting these high risk groups are needed if countries of the Greater Mekong Subregion are to achieve malaria elimination by 2030. The study will be conducted in malaria endemic areas of Lao PDR (Attapeu, Saravanh, Savannakhet and Khammouane Provinces) and Cambodia (Preah Vihear, Stung Treng and Ratanakiri Provinces) which have large forest going MMP populations. The aim of the study is to assess the effectiveness, acceptability, feasibility and cost-effectiveness of a personal protection package to reduce malaria transmission among mobile and migrant populations (MMPs) and the general population in their residing villages in Lao People's Democratic Republic (PDR) and Cambodia. The personal protection package comprises a long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and a behavioural change communication (BCC) package tailored to mobile and migrant populations. The study design is a stepped-wedge cluster-randomized controlled trial with nested mixed methods study. The stepped-wedge cluster randomized trial will estimate the effectiveness of a personal protection package provided to forest-going MMPs (the intervention) delivered by village malaria volunteers at the site (village/worksite) level on reducing Plasmodium spp. infections. Whilst the personal protection package will be provided to mobile and migrant populations in each village in a step-wise manner, primary and secondary outcomes relating to malaria testing will be collected in all consenting individuals in the village who present for malaria rapid diagnostic tests, whether they are mobile and migrant people or not.
The open stepped-wedge cluster-randomised controlled trial, randomized at the volunteer level (i.e. the volunteer and the village / workplaces they service), will be implemented between July 2021 to June 2022. The personal protection package for MMPs will be implemented sequentially in a minimum of ~488 villages serviced by approximately ~488 VMWs (~428 in Lao PDR and ~60 in Cambodia). Villages from each country will be randomised into 11 ordered blocks, with blocks transitioned from control (no personal protection package) to intervention (distribution of personal protection package) states at monthly intervals (10 blocks of 44 villages for the first 10 steps and a block of 48 villages transitioned at the last step). This follows an initial baseline control period of one-month at the start of the study
Approximately 11 RDTs per month will be undertaken in each study site (village/ worksite). Given the design we estimate that the study has power to detect a relative minimum detectable difference of 34% (OR = 0.66) in odds of RDT-detectable malaria infection due to the intervention (assuming a village intraclass correlation [ICC]= 0.42; 5% significance; 90% power and 1% RDT malaria prevalence).
For the stepped-wedged cluster randomized trial, both descriptive and primary outcome trial analyses will be performed. Using Stata version 15, differences in prevalence of Plasmodium spp. infections will be estimated across intervention and control periods using generalized linear mixed modelling (e.g. logit link function and binomial distribution) with crossed random effects for village and time, and intervention state, time and seasonality estimated as independent fixed factors. Temporal and spatial trends of Plasmodium spp. infections will also be explored including analysis of the effectiveness of the intervention across the study period. We will also explore any village-specific heterogeneity in effect by specifying a random effect for the intervention. Generalised linear mixed modelling will be extended to include model terms for country (main and interaction effects), and these will used to assess the extent of country-specific heterogeneity in intervention effect. The same approach will be used to assess risk group-specific heterogeneity (MMP, forest-goer, villager) in intervention effect.
Tipo de estudo
Inscrição (Antecipado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: Freya JI Fowkes, DPhil
- Número de telefone: +613 8506 2310
- E-mail: freya.fowkes@burnet.edu.au
Estude backup de contato
- Nome: Julia C Cutts, PhD
- Número de telefone: +61408397376
- E-mail: julia.cutts@burnet.edu.au
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion:
Mobile and migrant individuals aged 18 years and over in selected villages including:
- Traditional slash-and-burn and paddy field farming communities visiting their forest farms (commonly ethnic minority groups)
- Seasonal agricultural laborers
- Forest workers in the informal sector (hunters, small-scale gem/gold miners, people gathering forest products (precious timber, construction timber, rattan/bamboo)
- Transient or mobile camp residents associated with commercial projects (road/pipeline construction, large-scale logging, deep seaport projects, etc.)
- Formal and informal cross-border migrant workers
For qualitative research component, local health stakeholders meeting the following criteria will be eligible:
- Aged 18 years and over
- The local health stakeholders such as health centre staff, Operational District Malaria Supervisor (ODMS), and Provincial Malaria Supervisor (PMS), and basic health staff such as malaria unit staff in health centres, midwives, health assistants, district health officers and district focal person from CMPE and CNM
- Health staff members from HPA and Lao malaria community service organisations
Exclusion:
A village will be excluded from the study if:
The village has an VHV/VMW program operated by any organizations other than CMPE, CNM, HPA, malaria CSOs in Lao PDR The village has no malaria cases or API less than 1 in any of the past three years (2018 - 2020) The village has no MMPs The village has no VHV/VMW The village has a government health facility for provision of malaria services
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Prevenção
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Personal protection package
A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and mobile and migrant population-tailored behavioural change communication (BCC) package
|
A personal protection package that includes Long-lasting insecticidal hammock net (LLIHN), insect repellent (Icaridin), and MMP-tailored behavioural change communication (BCC) package
|
|
Sem intervenção: Control
No personal protection package
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Plasmodium spp. infection diagnosed by RDT
Prazo: Assessed weekly, longitudinally over 12 months
|
Change in the number of Plasmodium spp.
infections detected by RDT per week per village
|
Assessed weekly, longitudinally over 12 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Malária sintomática diagnosticada por RDT
Prazo: Avaliado semanalmente, longitudinalmente ao longo de 12 meses
|
Alteração no número de Plasmodium spp sintomáticos.
infecções detectadas por RDT por semana por aldeia
|
Avaliado semanalmente, longitudinalmente ao longo de 12 meses
|
|
Prevalência de anticorpos para Plasmodium spp.
Prazo: Avaliado semanalmente, longitudinalmente ao longo de 12 meses
|
Prevalência de anticorpos para Plasmodium spp.
determinado por Ensaio de Imunoabsorção Enzimática (ELISA) a partir de amostras de RDT e DBS
|
Avaliado semanalmente, longitudinalmente ao longo de 12 meses
|
|
Níveis de anticorpos para Plasmodium spp.
Prazo: Avaliado semanalmente, longitudinalmente ao longo de 12 meses
|
Níveis de anticorpos para Plasmodium spp.
determinado por Ensaio de Imunoabsorção Enzimática (ELISA) a partir de amostras de RDT e DBS
|
Avaliado semanalmente, longitudinalmente ao longo de 12 meses
|
|
Plasmodium spp. infection as determined by polymerase chain reaction (PCR) on RDT cassette samples
Prazo: Assessed weekly, longitudinally over 12 months
|
Change in the prevalence of Plasmodium spp.
infection as determined by polymerase chain reaction (PCR) from RDT cassette samples
|
Assessed weekly, longitudinally over 12 months
|
|
Plasmodium spp. infection as determined by polymerase chain reaction (PCR) on dried blood spot samples
Prazo: Assessed weekly, longitudinally over 12 months
|
Change in the prevalence of Plasmodium spp.
infection as determined by polymerase chain reaction (PCR) from dried blood spot (DBS) samples
|
Assessed weekly, longitudinally over 12 months
|
|
Plasmodium spp. infections with drug resistance mutations
Prazo: Assessed weekly, longitudinally over 12 months
|
Change in the prevalence of Plasmodium spp.
infection with drug resistance mutations.
|
Assessed weekly, longitudinally over 12 months
|
|
Prevalence of antibodies to vector salivary antigens
Prazo: Assessed weekly, longitudinally over 12 months
|
Levels of antibody biomarkers of vector exposure
|
Assessed weekly, longitudinally over 12 months
|
|
Levels of antibodies to vector salivary antigens
Prazo: Assessed weekly, longitudinally over 12 months
|
Levels of antibody biomarkers of vector exposure
|
Assessed weekly, longitudinally over 12 months
|
|
Levels of knowledge, attitude and practice regarding malaria prevention among MMPs
Prazo: At approximately 12 months
|
Focus group discussions
|
At approximately 12 months
|
|
Proportion of survey respondents (MMPs) who accept and are willing to use/ did use the personal protection package according to the protocol
Prazo: At approximately 12 months
|
Questionnaire
|
At approximately 12 months
|
Colaboradores e Investigadores
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Antecipado)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 388/21_forest_Cambodia_Laos
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .